CN115869351A - Composition containing eucalyptus oil and preparation method and application thereof - Google Patents
Composition containing eucalyptus oil and preparation method and application thereof Download PDFInfo
- Publication number
- CN115869351A CN115869351A CN202111143967.1A CN202111143967A CN115869351A CN 115869351 A CN115869351 A CN 115869351A CN 202111143967 A CN202111143967 A CN 202111143967A CN 115869351 A CN115869351 A CN 115869351A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- water
- soluble emulsifier
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000010642 eucalyptus oil Substances 0.000 title claims abstract description 45
- 229940044949 eucalyptus oil Drugs 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 56
- 239000003921 oil Substances 0.000 claims abstract description 40
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229940041616 menthol Drugs 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000011159 matrix material Substances 0.000 claims abstract description 15
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract 7
- 239000012071 phase Substances 0.000 claims description 46
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 37
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 21
- 229940057995 liquid paraffin Drugs 0.000 claims description 17
- 235000021355 Stearic acid Nutrition 0.000 claims description 16
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 16
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 16
- 239000008117 stearic acid Substances 0.000 claims description 16
- 239000003871 white petrolatum Substances 0.000 claims description 16
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 15
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000004945 emulsification Methods 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 230000001804 emulsifying effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 235000019271 petrolatum Nutrition 0.000 claims description 6
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 5
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 5
- 239000008387 emulsifying waxe Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 5
- 229920001993 poloxamer 188 Polymers 0.000 claims description 5
- 229940044519 poloxamer 188 Drugs 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 229920002675 Polyoxyl Polymers 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- -1 liquid paraffin Substances 0.000 claims description 4
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
- 229960001777 castor oil Drugs 0.000 claims description 3
- 229950004959 sorbitan oleate Drugs 0.000 claims description 3
- 229940060184 oil ingredients Drugs 0.000 claims description 2
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 239000002674 ointment Substances 0.000 abstract description 17
- 238000010521 absorption reaction Methods 0.000 abstract description 8
- 230000000241 respiratory effect Effects 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 2
- 239000006185 dispersion Substances 0.000 abstract description 2
- 239000006071 cream Substances 0.000 description 64
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 28
- 235000019198 oils Nutrition 0.000 description 27
- 238000011156 evaluation Methods 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 239000002994 raw material Substances 0.000 description 5
- 230000004202 respiratory function Effects 0.000 description 5
- 231100000245 skin permeability Toxicity 0.000 description 5
- 206010013952 Dysphonia Diseases 0.000 description 4
- 208000010473 Hoarseness Diseases 0.000 description 4
- 206010028748 Nasal obstruction Diseases 0.000 description 4
- 206010039101 Rhinorrhoea Diseases 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000036071 Rhinorrhea Diseases 0.000 description 3
- 206010051788 Sticky skin Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004081 cilia Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001256 steam distillation Methods 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 2
- 240000005636 Dryobalanops aromatica Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000166124 Eucalyptus globulus Species 0.000 description 2
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 2
- 241000218195 Lauraceae Species 0.000 description 2
- 240000003553 Leptospermum scoparium Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000075634 Cyperus rotundus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000245214 Mentha canadensis Species 0.000 description 1
- 235000001878 Mentha haplocalyx Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a composition and a preparation method thereof. A provided composition includes: eucalyptus oil, menthol, an oil phase matrix, an oil-soluble emulsifier, a water-soluble emulsifier and water. The eucalyptus oil and the menthol are prepared into the composition, and the product with definite effect, convenient use, good transdermal absorption and small side effect is provided for relieving the respiratory discomfort caused by the cold. The composition prepared by the invention is characterized in that one phase of immiscible water phase and oil phase is dispersed in the other phase in a small droplet state under the action of a specific emulsifier to form a viscous heterogeneous dispersion system, and compared with the traditional ointment, the composition does not generate sticky and uncomfortable skin feel after being applied, does not pollute clothes, is convenient for daily use, and has better transdermal effect.
Description
Technical Field
The invention relates to the field of biological medicines, and in particular relates to a composition containing eucalyptus oil as well as a preparation method and application thereof.
Background
The oleum Eucalypti is volatile oil obtained by steam distillation of Eucalyptus globulus Labill of Myrtaceae, cinnamomum camphora of Lauraceae, or other plants of the same genus of the above two families. Has wide pharmacological effects, such as antibacterial, antiinflammatory, respiratory function improving and transdermal absorption promoting. In the aspect of antibiosis: the eucalyptus oil has strong broad-spectrum antibacterial effect, and has good antibacterial effect on Staphylococcus aureus, staphylococcus albus, streptococcus, mycobacterium tuberculosis, etc. In terms of anti-inflammation: the eucalyptus oil can obviously inhibit the expression and activation of various inflammatory factors, especially nuclear factor and tumor necrosis factor (NF-KB). In improving respiratory function: by alkalizing mucus, the pH value of mucus is recovered to a normal value, the secretion is regulated to recover the proportion of serous fluid and mucus, a normal cilium swinging space is provided, cilia can be directly stimulated to swing quickly, and the mucus and cilia clearing function is enhanced. In the aspect of promoting transdermal absorption: the eucalyptus oil has the liquid crystal structure in the skin which is disturbed, promotes the percutaneous absorption of the eucalyptus oil and other active ingredients, and is particularly suitable for being made into products such as paste for external use. However, no suitable ointment prepared with eucalyptus oil can be used.
The patent publication No. CN107617034A is a Chinese patent application of tea tree massage cream for relieving cold of children, and is characterized in that the massage cream is prepared from nutgrass flatsedge oil, eucalyptus oil, tea tree essential oil, kiwi fruit oil, shea butter, coconut oil, sunflower oil, jojoba oil and beeswax, and symptoms of cold of infants and children are relieved by massaging, touching and the like. The product is an ointment formula, has sticky skin feeling when in use, easily pollutes clothes, and has low transdermal quantity and poor effect.
Thus, further improvements are needed to prepare suitable formulations containing eucalyptus oil.
Disclosure of Invention
The present invention solves at least one of the above technical problems to a certain extent. The invention provides an external ointment containing eucalyptus oil, which can relieve respiratory discomfort caused by cold. The inventor creatively discovers in the research process that eucalyptus oil and menthol are prepared into cream, and provides a product with definite effect, convenient use, good transdermal absorption and small side effect for relieving respiratory discomfort caused by cold. The cream prepared by the invention is characterized in that one phase of immiscible water phase and oil phase is dispersed in the other phase in a small droplet state under the action of a specific emulsifier to form a viscous heterogeneous dispersion system, and compared with the traditional ointment, the cream does not generate sticky and uncomfortable skin feeling after being smeared, does not pollute clothes, is convenient for daily use, and has better transdermal effect.
To this end, a first aspect of the invention provides a composition. According to an embodiment of the invention, the composition comprises: eucalyptus oil, menthol, oil phase matrix, emulsifier,
wherein the emulsifier comprises an oil-soluble emulsifier and a water-soluble emulsifier;
the oil-soluble emulsifier is at least one of glyceryl monostearate, emulsifying wax, sorbitan oleate, cetearyl alcohol and polyoxyl (40) ester;
the water-soluble emulsifier is at least one selected from triethanolamine, PEG40 hydrogenated castor oil, polysorbate 80 and poloxamer 188.
The traditional product for relieving the discomfort of the nasopharynx part needs to be orally taken, sprayed or directly washed, has large side effect and is easy to cause the damage of the nasal mucosa. Generally, the preparation for relieving respiratory tract discomfort is ointment, has sticky skin feel when in use, easily pollutes clothes, and has low transdermal dose and poor effect. The eucalyptus oil has the functions of resisting inflammation, resisting bacteria and improving the respiratory function, the menthol is extracted from the leaves and stems of the mint, has the effects of resisting bacteria and viruses, relieving and relieving cough, and the inventor finds that the eucalyptus oil and the menthol in a specific dosage proportion are prepared into a cream (such as a massage cream) to relieve the respiratory discomfort caused by cold in the research process. In addition, the eucalyptus oil, the menthol and a proper emulsifier are prepared into the cream, so that the problem of sticky feeling of the cream in use is solved, the skin penetration rate is higher, and the effect is better.
According to a preferred embodiment of the present invention, the oil-soluble emulsifier is glyceryl monostearate and the water-soluble emulsifier is triethanolamine. Therefore, the state of the cream body can be further improved, so that the cream body is thick, fine and smooth, has good touch feeling, does not have sticky and greasy skin feeling, and has good transdermal effect.
According to an embodiment of the invention, the oily phase base is selected from at least one of stearic acid, liquid paraffin, white petrolatum.
According to an embodiment of the invention, the oil phase base is stearic acid, liquid paraffin and white petrolatum.
According to an embodiment of the invention, the composition comprises, in parts by weight:
3 to 30 parts of eucalyptus oil,
0.3 to 10 portions of menthol crystal,
1 to 10 parts of an oil-soluble emulsifier, and
0.1 to 1 portion of water-soluble emulsifier.
The composition containing the eucalyptus oil, the menthol, the oil-soluble emulsifier and the water-soluble emulsifier in a specific dosage ratio can further improve the capacity of the medicine for improving the respiratory tract function and relieving the respiratory tract discomfort caused by cold, and has better transdermal absorption effect.
According to an embodiment of the present invention, the composition further comprises, in parts by weight:
10 to 40 parts of oil phase matrix, preferably 14 to 27 parts of oil phase matrix.
According to an embodiment of the present invention, the oil phase base includes 10 to 15 parts by weight of stearic acid, 2 to 5 parts by weight of liquid paraffin, and 3 to 5 parts by weight of white petrolatum.
According to an embodiment of the invention, the composition comprises, in parts by weight:
3 to 30 parts of eucalyptus oil,
0.3 to 10 parts of menthol crystal,
10 to 40 parts of oil phase matrix,
1 to 10 portions of oil-soluble emulsifier,
0.1 to 1 part of a water-soluble emulsifier, and
60-80 parts of water.
According to an embodiment of the invention, the composition comprises, in parts by weight:
5 to 15 parts of eucalyptus oil,
0.5 to 3 parts of menthol crystal,
10 to 18 parts of stearic acid, and the like,
1 to 6 parts of glycerin monostearate,
1 to 6 parts of liquid paraffin,
3 to 8 parts of white vaseline,
0.1 to 1 part of triethanolamine, and
60-80 parts of water.
According to an embodiment of the invention, the composition comprises, in parts by weight:
7 to 12 parts of eucalyptus oil,
1 to 2 parts of menthol crystal,
10 to 15 parts of stearic acid, wherein,
2 to 5 parts of glycerin monostearate,
2 to 4 parts of liquid paraffin,
3 to 5 parts of white vaseline,
0.2 to 0.6 part of triethanolamine, and
60-80 parts of water.
The formula of the composition further improves the capacity of the medicament for improving respiratory function and relieving respiratory discomfort caused by cold, has better transdermal absorption effect, and further improves the state of the cream body, so that the cream body is thick, fine and smooth, has good touch feeling and does not have sticky and greasy skin feel.
In a second aspect, the present invention provides a method of preparing the composition of the first aspect. According to an embodiment of the invention, the method comprises:
(1) Heating the oil phase matrix and the oil-soluble emulsifier to melt so as to obtain an oil phase;
(2) Heating the water-soluble emulsifier and water to isothermal with the oil phase so as to obtain an aqueous phase;
(3) Mixing and emulsifying the oil phase, the eucalyptus oil, the menthol and the water phase to obtain the composition.
According to the embodiment of the invention, the temperature of the emulsification treatment is 50-80 ℃, and the time of the emulsification treatment is more than 10 min.
According to an embodiment of the present invention, the stirring speed of the emulsification treatment is 3000 to 30000rpm.
The beneficial effects obtained by the invention are as follows:
the invention prepares the eucalyptus oil and the menthol with specific dosage and a specific emulsifier into the cream, and the cream has thick and fine cream body, good touch feeling, no sticky and greasy skin feeling and good transdermal effect. It can be applied to nasal wing, chest, back, etc., and absorbed by massage to relieve respiratory tract discomfort caused by common cold. The components in the cream provided by the invention can be absorbed through skin and do not contact with nasal mucosa, various components contained in the cream are mild and non-irritant, and transdermal experiments show that the transdermal effect of the active ingredients is good, so that the effect of relieving respiratory tract discomfort caused by cold can be ensured.
Drawings
The above and/or additional aspects and advantages of the present invention will become apparent and readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:
fig. 1 shows the average permeability comparison results of the pastes prepared from formulations 1, 4, 5 in example 6.
Detailed Description
The following detailed description of embodiments of the invention is intended to be illustrative, and is not to be construed as limiting the invention.
The traditional product for relieving the discomfort of the nasopharynx part needs to be orally taken, sprayed or directly washed, has large side effect and is easy to cause the damage of the nasal mucosa. And the preparation for relieving the respiratory tract discomfort is ointment, so that the ointment has sticky skin feel and is easy to pollute clothes when in use, and the transdermal quantity is low and the effect is poor. The eucalyptus oil has the functions of resisting inflammation, resisting bacteria and improving the respiratory function, and the inventor finds that the eucalyptus oil and the menthol are combined to prepare the cream to relieve the respiratory discomfort caused by cold in the research process. In addition, the eucalyptus oil, the menthol and proper auxiliary materials are prepared into the emulsifiable paste (such as massage cream), so that the problem of sticky feeling of the ointment in use is solved, the skin penetration rate is higher, and the effect is better.
According to a specific embodiment of the present invention, there is provided a massage cream including:
3 to 30 parts of eucalyptus oil,
0.3 to 10 portions of menthol crystal,
10 to 40 parts of oil phase matrix,
1 to 10 portions of oil-soluble emulsifier,
0.1 to 1 part of a water-soluble emulsifier, and
60-80 parts of water.
The oil phase matrix of the invention includes but is not limited to at least one of stearic acid, liquid paraffin and white vaseline. In some embodiments, the oil phase base comprises stearic acid, liquid paraffin, and white petrolatum.
According to an embodiment of the present invention, the oil-soluble emulsifier is selected from at least one of glyceryl monostearate, emulsifying wax, sorbitan oleate, cetearyl alcohol, polyoxyl (40) ester.
According to an embodiment of the invention, the water soluble emulsifier is selected from at least one of triethanolamine, PEG40 hydrogenated castor oil, polysorbate 80, poloxamer 188.
According to a specific embodiment of the present invention, there is provided a massage cream including:
5 to 15 parts of eucalyptus oil,
0.5 to 3 parts of menthol crystal,
10 to 18 parts of stearic acid, and the like,
1 to 6 parts of glycerin monostearate,
1 to 6 parts of liquid paraffin,
3 to 8 parts of white vaseline,
0.1 to 1 part of triethanolamine, and
60-80 parts of water.
According to a specific embodiment of the present invention, there is provided a method for preparing a massage cream, including:
(1) Heating the oil phase matrix and the oil-soluble emulsifier to melt so as to obtain an oil phase;
(2) Heating the water-soluble emulsifier and water to isothermal with the oil phase so as to obtain an aqueous phase;
(3) And mixing and emulsifying the oil phase, the eucalyptus oil, the menthol and the water phase so as to obtain the massage cream.
According to the embodiment of the present invention, the temperature of the emulsification treatment is 50 to 80 ℃ (for example, the emulsification temperature may be 50 ℃, 55 ℃, 60 ℃, 65 ℃, 70 ℃, 75 ℃, 80 ℃), and the time of the emulsification treatment is 10min or more (for example, the emulsification time may be 10min, 15min, 20min, 25min, 30min, 1h, 2h, etc.);
the stirring speed of the emulsification treatment is 3000 to 30000rpm (for example, the stirring speed of the emulsification treatment may be 3000rpm, 3500rpm, 4000rpm, 4500rpm, 5000rpm, 6000rpm, 7000rpm, 10000rpm, 20000rpm, 30000rpm, etc.).
Under the condition, the emulsifying effect can be further improved, and the massage cream with thick cream body, fineness, good touch feeling and no sticky and greasy skin feeling is obtained.
The eucalyptus oil is volatile oil extracted from Eucalyptus globulus Labill, cinnamomum camphora (L.) Presl of Lauraceae, or other plants of the same genus of the above two families by steam distillation. Containing eucalyptol (C) 10 H 18 O) should not be less than 60.0%. Herein, menthol is a saturated cyclic alcohol obtained by steam distillation, freezing and recrystallization of fresh stems and leaves of Mentha haplocalyx of Labiatae, and is l-1-methyl-4-isopropylcyclohexanol-3. Contains menthol (C) 10 H 20 O) must not be less than 80%.
In some preferred embodiments, the massage cream comprises the following components in parts by weight: 7 to 12 parts of eucalyptus oil, 1 to 2 parts of menthol, 10 to 15 parts of stearic acid, 2 to 5 parts of glycerin monostearate, 2 to 5 parts of liquid paraffin, 3 to 5 parts of white vaseline, 0.2 to 0.6 part of triethanolamine and 60 to 80 parts of water.
In some preferred embodiments, the massage cream comprises 3.5 to 5 parts by weight of glyceryl monostearate and 0.4 to 0.6 part by weight of triethanolamine.
The respiratory discomfort caused by cold includes rhinorrhea, nasal obstruction, breathing discomfort and hoarseness caused by cold.
In some preferred embodiments, the weight ratio of eucalyptus oil to menthol is 8. The menthol is preferably levo-menthol. The weight ratio of the eucalyptus oil to the menthol is within the range, and the maximum drug effect can be exerted, so that nasal discharge and nasal obstruction can be relieved, and hoarseness can be improved.
In some more preferred embodiments, a massage cream is provided that includes: 8 parts by weight of eucalyptus oil, 1 part by weight of menthol, 12 parts by weight of stearic acid, 3.5 parts by weight of glyceryl monostearate, 2.5 parts by weight of liquid paraffin, 4.5 parts by weight of white vaseline, 0.4 part by weight of triethanolamine, and 68 parts by weight of water.
The invention also provides a preparation method of the massage cream, which comprises the following steps:
heating stearic acid, glyceryl monostearate, liquid paraffin and white vaseline to melt to obtain oil phase;
heating triethanolamine and water to be isothermal with the oil phase to serve as a water phase;
mixing the oil phase with eucalyptus oil and menthol, mixing with the water phase, and emulsifying to obtain massage cream.
The scheme of the invention will be explained with reference to the examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are conventional products which are commercially available, and are not indicated by manufacturers.
EXAMPLE 1 preparation of massage cream
Example 1 provides a massage cream formulation and method of preparation. Firstly, raw materials are prepared according to the component proportions listed in table 1, and the parts in table 1 are weight proportions.
Table 1 prescription 1-5 raw material ratio
Formulas 1-4 massage creams were prepared as described below:
stearic acid, glyceryl monostearate, liquid paraffin and white vaseline are heated to 80 deg.C to melt into an oil phase, and triethanolamine (or PEG40 hydrogenated castor oil) and distilled water are additionally heated to the same temperature as the oil phase (as the aqueous phase). Adding the eucalyptus oil and the menthol into the oil phase, adding the water phase into the oil phase, shearing and emulsifying at 50-80 ℃ for 15 minutes (6000 rpm), continuously stirring until the mixture is milky semisolid, and then stirring and cooling to room temperature.
heating vaseline, liquid paraffin and medium chain triglyceride together to melt, cooling to 50 deg.C, adding oleum Eucalypti containing dissolved Mentholum, stirring, and condensing.
The massage cream prepared according to the prescription 1-4 has thick paste, good state and good touch. Prescription 5 is thick paste, greasy touch.
Example 2 evaluation of drug efficacy
The 48 patients with symptoms of rhinorrhea, nasal obstruction, hoarseness and the like caused by cold are averagely divided into 4 groups, and the ointment prepared by the formulas 1 to 3 and 5 in the example 1 is respectively applied, and the treatment effect is shown in the following table 2:
table 2 evaluation of drug efficacy of ointments prepared in prescriptions 1 to 3 and 5
The results in table 2 show that the massage cream prepared according to the formula of the formula 1 has quick effect, relieves rhinorrhea and nasal obstruction and has obvious effect of improving hoarseness, while the massage creams prepared according to the formulas of the formulas 2 and 3 only contain single components of eucalyptus oil or menthol, although the effect time is equivalent to that of the formula 1, the efficacy is very little. The ointment prepared according to the formula of the formula 5 has a certain drug effect, but is thick, not emulsified by a specific emulsifier, poor in skin feel, greasy in touch, unobvious in cool feeling and slow in effect.
Example 3 optimization of emulsifier types
Massage creams prepared by recipes 6 to 12 were obtained according to the same method of preparing massage creams using recipes 1 to 4 in example 1 using the recipe in table 3 below.
Table 3 raw material ratio of prescription 1, 6-12 and cream state evaluation
The results in table 3 show that the massage cream prepared by using the emulsifier combination of specific oil-soluble emulsifiers (such as glyceryl monostearate, cetearyl alcohol, emulsifying wax, polyoxyl (40) ester) and specific water-soluble emulsifiers (such as triethanolamine, polysorbate 80 and poloxamer 188) has good shape and touch; however, by using other oil-soluble and water-soluble emulsifiers, such as the combination of glyceryl monocaprylate and triethanolamine in formula 6, or the combination of glyceryl monostearate and sodium lauryl sulfate in formula 10, the prepared ointment cannot be solidified into an ointment and is not easy to apply. Therefore, only by using the combination of the specific oil-soluble emulsifier and the specific water-soluble emulsifier of the present invention, a massage cream having a good shape and touch can be obtained.
EXAMPLE 4 optimization of emulsifier dosage
Massage creams prepared by recipes 13 to 21 were obtained according to the same method of preparing massage creams using recipes 1 to 4 in example 1, using recipes in tables 4 and 5 below.
Table 4 recipe 13-17 raw material ratio and massage cream state evaluation
TABLE 5 evaluation of 18-21 raw material ratios and massage cream state
The results in tables 4 and 5 show that the massage cream prepared by the formula containing 2 to 5 weight parts of glyceryl monostearate and 0.4 to 0.6 weight part of triethanolamine has better emulsifying effect and touch feeling and is not greasy, and particularly, the massage cream prepared by the formula containing 3.5 to 5 weight parts of glyceryl monostearate and 0.4 to 0.6 weight part of triethanolamine has better effect. However, the massage cream lacks any one of the oil-soluble emulsifier and the water-soluble emulsifier, and the cream properties meeting the requirements cannot be obtained.
Example 5 sensory evaluation
5 out of 30 testers were arbitrarily selected and used the massage creams prepared according to the above-mentioned prescription, and the skin touch feeling of the massage creams was evaluated by the 5 testers according to the following table 6. Table 7 shows the scores of 5 trial workers on the massage creams prepared by each prescription.
TABLE 6 skin tactility score Standard for massage cream
TABLE 7 summary of the scores of the probands on the massage creams prepared with each prescription
| Prescription | Trial person | 1 | |
|
|
|
Average out |
| |
7 | 8 | 9 | 8 | 9 | 8.2 | |
| |
7 | 7 | 8 | 7 | 8 | 7.4 | |
| |
7 | 8 | 8 | 8 | 8 | 7.8 | |
| |
7 | 8 | 9 | 8 | 8 | 8 | |
| |
6 | 5 | 6 | 4 | 6 | 5.4 | |
| |
7 | 8 | 8 | 9 | 7 | 7.8 | |
| Prescription 8 | 8 | 9 | 8 | 8 | 7 | 8 | |
| Prescription 9 | 8 | 7 | 7 | 9 | 8 | 7.8 | |
| Prescription 11 | 7 | 7 | 8 | 7 | 7 | 7.2 | |
| Prescription 12 | 8 | 7 | 9 | 7 | 7 | 7.6 | |
| Prescription 13 | 6 | 6 | 5 | 5 | 6 | 5.6 | |
| Prescription 14 | 6 | 7 | 6 | 5 | 7 | 6.2 | |
| Prescription 15 | 7 | 6 | 7 | 7 | 6 | 6.6 | |
| Prescription 16 | 7 | 8 | 8 | 7 | 8 | 7.6 | |
| Prescription 17 | 8 | 9 | 8 | 7 | 7 | 7.8 | |
| Prescription 19 | 8 | 7 | 6 | 7 | 7 | 7 | |
| Prescription 20 | 7 | 8 | 9 | 9 | 8 | 8.2 | |
| Prescription 21 | 8 | 8 | 9 | 9 | 6 | 8 |
The testers have an average score of 6 or more for the massage cream, and slight greasy feeling is the qualified standard of the skin feeling of the massage cream. According to the results shown in table 7, it is demonstrated that the massage cream prepared by using the emulsifier combination of the specific oil-soluble emulsifier of the present invention (e.g., glyceryl monostearate, cetearyl alcohol, emulsifying wax, polyoxy (40) ester) and the specific water-soluble emulsifier (e.g., triethanolamine, polysorbate 80, poloxamer 188) has a good feel to the touch without greasiness compared to the ointment, and particularly, the massage cream prepared by using the formula containing 2 to 5 parts by weight of glyceryl monostearate and 0.4 to 0.6 part by weight of triethanolamine has a further improved feel to the touch. The massage cream prepared by 3.5-5 parts by weight of glyceryl monostearate and 0.4-0.6 part by weight of triethanolamine in the prescription has better effect.
Example 6
Meanwhile, the skin permeability of the massage cream prepared by the formulas 1 and 4 and the ointment prepared by the formula 5 in the example 1 are compared, a Franz transdermal absorption diffusion cell is adopted for experiment, physiological saline containing 3% fatty alcohol-polyoxyethylene ether glucoside is used as receiving liquid, the temperature of the diffusion cell is 32 ℃, the stirring speed of a rotor is 400RPM, and 0.5g of the sample is respectively smeared on a simulated biological membrane and a back lining is added to prevent volatilization. The average skin permeability was compared at different times, 0 hours, 0.5 hours, 1 hour, 2 hours, 4 hours and 6 hours, respectively. The results are shown in table 8 below and fig. 1.
TABLE 8 skin Permeability at different times
| Time (hours) | |
|
|
| 0 | 0 | 0 | 0 |
| 0.5 | 0.14 | 0.17 | 0.05 |
| 1 | 0.38 | 0.35 | 0.18 |
| 2 | 0.84 | 0.80 | 0.38 |
| 4 | 1.78 | 1.52 | 0.82 |
| 6 | 2.12 | 2.01 | 1.02 |
As can be seen from Table 8 and the results of FIG. 1, the skin permeability of the massage cream prepared by the formula of the present invention is significantly higher than that of the ointment, and the skin permeability of the eucalyptus oil can be significantly improved after the massage cream is prepared into the cream.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (10)
1. A composition, comprising: eucalyptus oil, menthol, oil phase matrix, emulsifier,
wherein the emulsifier comprises an oil-soluble emulsifier and a water-soluble emulsifier;
the oil-soluble emulsifier is at least one selected from glyceryl monostearate, emulsifying wax, sorbitan oleate, cetearyl alcohol and polyoxyl (40) ester;
the water-soluble emulsifier is at least one selected from triethanolamine, PEG40 hydrogenated castor oil, polysorbate 80 and poloxamer 188.
2. The composition of claim 1, wherein the oil-soluble emulsifier is glycerol monostearate and the water-soluble emulsifier is triethanolamine;
optionally, the oil phase matrix is selected from at least one of stearic acid, liquid paraffin, white vaseline;
optionally, the oil phase base is stearic acid, liquid paraffin and white petrolatum.
3. The composition according to claim 1, comprising, in parts by weight:
3 to 30 parts of eucalyptus oil,
0.3 to 10 parts of menthol crystal,
1 to 10 parts of an oil-soluble emulsifier, and
0.1 to 1 portion of water-soluble emulsifier.
4. The composition of claim 3, further comprising, in parts by weight:
10 to 40 parts of oil phase matrix, preferably 14 to 27 parts of oil phase matrix.
5. The composition according to claim 4, wherein the oil phase base comprises 10 to 15 parts by weight of stearic acid, 2 to 5 parts by weight of liquid paraffin, and 3 to 5 parts by weight of white petrolatum.
6. The composition according to claim 1, comprising, in parts by weight:
3 to 30 parts of eucalyptus oil,
0.3 to 10 parts of menthol crystal,
10 to 40 parts of oil phase matrix,
1 to 10 parts of oil-soluble emulsifier,
0.1 to 1 part of a water-soluble emulsifier, and
60-80 parts of water.
7. The composition according to claim 1, comprising, in parts by weight:
5 to 15 parts of eucalyptus oil,
0.5 to 3 parts of menthol crystal,
10 to 18 parts of stearic acid, and the like,
1 to 6 parts of glycerin monostearate,
1 to 6 parts of liquid paraffin,
3 to 8 parts of white vaseline,
0.1 to 1 part of triethanolamine, and
60-80 parts of water.
8. A method of preparing the composition of any one of claims 1 to 7, comprising:
(1) Heating the oil phase matrix and the oil-soluble emulsifier to melt so as to obtain an oil phase;
(2) Heating the water-soluble emulsifier and water to isothermal with the oil phase so as to obtain an aqueous phase;
(3) Mixing and emulsifying the oil phase, the eucalyptus oil, the menthol and the water phase to obtain the composition.
9. The process according to claim 8, wherein the temperature of the emulsification treatment is 50 to 80 ℃ and the time of the emulsification treatment is 10min or more,
optionally, the stirring speed of the emulsification treatment is 3000-30000 rpm.
10. Use of a composition according to any one of claims 1 to 7, or a composition prepared by the process of claim 8 or 9, in the manufacture of a medicament for alleviating respiratory distress caused by colds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111143967.1A CN115869351A (en) | 2021-09-28 | 2021-09-28 | Composition containing eucalyptus oil and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111143967.1A CN115869351A (en) | 2021-09-28 | 2021-09-28 | Composition containing eucalyptus oil and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115869351A true CN115869351A (en) | 2023-03-31 |
Family
ID=85763560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111143967.1A Pending CN115869351A (en) | 2021-09-28 | 2021-09-28 | Composition containing eucalyptus oil and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115869351A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116265023A (en) * | 2021-12-16 | 2023-06-20 | 北京远大九和药业有限公司 | Pharmaceutical composition for preventing and/or treating ear infection, and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906466A (en) * | 2015-06-29 | 2015-09-16 | 湖南中医药大学 | Eucalyptus leaf cream and preparation method thereof |
| CN107441175A (en) * | 2017-09-05 | 2017-12-08 | 肇庆高新区国专科技有限公司 | One Plant Extracts and preparation method thereof |
-
2021
- 2021-09-28 CN CN202111143967.1A patent/CN115869351A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906466A (en) * | 2015-06-29 | 2015-09-16 | 湖南中医药大学 | Eucalyptus leaf cream and preparation method thereof |
| CN107441175A (en) * | 2017-09-05 | 2017-12-08 | 肇庆高新区国专科技有限公司 | One Plant Extracts and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李莉等: "中草药挥发油类透皮吸收促进作用研究进展", 中国新药杂志, vol. 17, no. 11, pages 914 - 918 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116265023A (en) * | 2021-12-16 | 2023-06-20 | 北京远大九和药业有限公司 | Pharmaceutical composition for preventing and/or treating ear infection, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106361599A (en) | Multi-vegetable-oil-containing infantile eczema care cream | |
| KR102257342B1 (en) | Composition for antimicrobial and anti-inflammatory activities and manufacturing method thereof | |
| WO1992006701A1 (en) | Preparation of concentrated fluid symphytum extracts, therapeutic forms and methods of use | |
| WO2004082597A2 (en) | Homeopathic formulations useful for treating pain and/or inflammmation | |
| CN104147533A (en) | Blood-activating, stasis-resolving and pain-relieving cream and preparation method thereof | |
| CN108992451A (en) | A kind of emulsifiable paste and preparation method thereof with anti-inflammatory anti-itch antibiotic effect | |
| WO2010097643A1 (en) | Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite | |
| CN108143646A (en) | A kind of antipruritic cream composition of glycyrrhetinic acid and preparation method thereof | |
| CN115869351A (en) | Composition containing eucalyptus oil and preparation method and application thereof | |
| US8758836B2 (en) | Method and formulation for treating dry ear inflammation with cortisone | |
| CN114588078A (en) | Self-emulsifying functional oil phase and preparation method and application thereof | |
| JP5756676B2 (en) | Topical skin preparation | |
| WO2004105689A2 (en) | Topical composition for the treatment of skin disorders and methods of using the same | |
| CN110403998A (en) | A kind of composition, Chinese medical extract and the Chinese materia medica preparation of anti-acne and reparation acne flesh | |
| CN115518127A (en) | Antibacterial, anti-inflammatory, detumescence and itching relieving cream and preparation method thereof | |
| CN110812377B (en) | Acne treatment and repair composition and application thereof | |
| PT2011504E (en) | Skin cream for treatment and/or cleaning of skin for neurodermitis | |
| CN114344219A (en) | Aromatic plant composition for treating red swelling, itching and pain of skin and preparation method thereof | |
| Ruiz et al. | Skin creams made with olive oil | |
| CN114129649A (en) | Cold compress gel capable of promoting skin barrier repair and nursing | |
| Price | How essential oils enter the body | |
| Gandomkar et al. | Development of an anti-acne cream based on natural oils: Investigation of the effect of ingredients on rheology, texture properties, and physical stability | |
| CN113995701B (en) | Composition for removing acnes and acne marks as well as preparation method and application thereof | |
| CN113713000B (en) | Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof | |
| KR102652806B1 (en) | A method of producing a cosmetic composition containing hempseed oil and a cosmetic composition containing hempseed oil produced thereby having an atopic improvement effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |